⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALGS News
Aligos Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
ALGS
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
globenewswire.com
ALGS
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
globenewswire.com
ALGS
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ALGS
Algenesis Labs Achieves ISO 14001 Certification, Strengthening Commitment to Sustainable Manufacturing
prnewswire.com
ALGS
Form 8-K
sec.gov
ALGS
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
globenewswire.com
ALGS
Form 8-K
sec.gov
ALGS
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
globenewswire.com
ALGS
Algenesis Cuts Carbon Footprint by Up to 65% with Soleic® Bio-Based Materials
prnewswire.com
ALGS